Cantor Fitzgerald Reiterates Overweight on Mirum Pharmaceuticals, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Joshua Schimmer has reiterated an Overweight rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and maintained a $50 price target for the company's stock.
November 15, 2023 | 2:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst reaffirms Overweight rating and maintains a $50 price target on Mirum Pharmaceuticals.
The reiteration of an Overweight rating by a reputable analyst like Joshua Schimmer suggests a positive outlook on Mirum Pharmaceuticals' stock. The maintained price target of $50 indicates a belief in the company's potential to reach or exceed this value, which could influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100